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Abstract
Background—Genome-wide association studies (GWAS) have identified numerous common
SNPs associated with prostate cancer (CaP) risk in men of European descent. This study evaluates
GWAS SNPs associated with CaP in African Americans (AA) and European Americans (EA).
Methods—800 SNPs were genotyped, including 32 from European-based GWAS and 35
flanking SNPs, in 417 AA and 455 EA cases from the NC-LA Prostate Cancer Project (PCaP) and
compared to 925 AA and 1,687 EA controls from Illumina's iControlDB. The 32 GWAS SNPs
were evaluated for their predictive power to discriminate between cases and controls using ROC
curves.
Results—Of the 32 GWAS SNPs, 13 were significant at P < 0.05 in EA and 4 in AA
(rs6983267, rs7017300, rs1859962, rs6501455). Three of 35 flanking SNPs, all from chromosome
8q, reached study-wide significance (p < 3.5×10−5); two in AA (rs10505476 rs6985504) and one
in EA (rs16901970). Among the remaining 656 SNPs, two were associated with CaP (p <
3.5×10−5): rs1472606 (OR: 1.43 in EA) and rs9351265 (OR: 1.48 in AA) both in intergenic
regions. For the 32 GWAS SNPs, ROC plots yielded AUC estimates too low for clinical use (EA
AUC= 0.60 and AA AUC= 0.56).
Conclusions—This study confirms a large proportion of CaP associated regions implicated by
European-based GWAS and provides evidence that some regions may be important in AA CaP
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risk. Despite the identification of a large panel of GWAS replicated SNPs for CaP, this panel is
not appropriate for clinical screening.
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Introduction
Despite widespread screening and improved treatment, prostate cancer (CaP) remains a
major public health concern with more than 192,290 cases diagnosed in the US annually [1].
Significant racial disparities exist, with African Americans (AA) facing a 70% higher
incidence of CaP compared to Caucasian/European Americans (EA), higher than any other
ethnic group in the US [2] . Quantitative estimates from twin studies indicate that 42% of the
variation in CaP risk may be attributed to genetic components—higher than for any other
type of common human cancer [3]. Genome-wide association studies (GWAS) have
identified a number of common SNPs that are associated with CaP risk in populations of
European descent [4-7], although these SNPs explain only a small fraction of the heritable
component. Replication and fine mapping studies of these SNPs have focused largely on
Europeans [8-11]. AAs have been evaluated less frequently despite their higher risk of CaP
[5,8,12-15].
While the SNPs identified from GWAS show association with disease, little evidence
suggests that they are causal, but rather are markers that are in linkage disequilibrium (LD)
with as yet unidentified causal variants. Identifying SNPs responsible for CaP susceptibility
is particularly important because they may provide insight into the biology of the disease
and a basis on which to develop new treatments. In addition, such causal SNPs provide the
potential to improve screening and identification of high risk patients, and an avenue toward
personalized medicine. Extending replication studies and investigating populations with
different LD structure may help identify the full complement of causal/functional genetic
variation explaining CaP heritability. AA populations are of particular interest toward this
end because of their high risk, higher genetic diversity, and finer grained LD structure.
Publically available genetic data sets and new tools for integrating linkage, molecular, and
GWAS data make it possible to better inform SNP selection for genetic investigation. Here
we use a newly available bioinformatics tool to construct a SNP panel based on GWAS
results and functional prediction. Using this panel, we describe an analysis that compared
publically available iControlDB data (http://www.illumina.com/science/icontroldb.ilmn) to
newly generated data from EA and AA CaP cases from North Carolina. Finally, the utility of
a set of a priori SNPs from previous GWAS studies was assessed for their predictive
accuracy in discriminating CaP cases from controls.
Subjects and Methods
Study population
PCaP is a multi-disciplinary, population-based, case-only study, designed to address racial
differences in CaP, which has been described previously [16]. Briefly, 1,133 AA and 1,128
EA incident CaP cases were rapidly ascertained and recruited in North Carolina and
Louisiana, respectively. Subjects self-reporting as black/African American or white/
Caucasian American, between 40-79 years of age at diagnosis with histologically confirmed
adenocarcinoma of the prostate were eligible to participate. Informed consent was obtained
from all subjects prior to blood and questionnaire collection. The study was approved by the
University of North Carolina at Chapel Hill (UNC-CH) and Louisiana State University
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Health Sciences Center (LSUHSC) Institutional Review Boards and the Department of
Defense Human Subjects Research Review Board. Because of delays in recruitment in
Louisiana following Hurricane Katrina, this analysis is limited to North Carolina cases
enrolled from September 2004 through December of 2007 with available DNA.
Study questionnaire information was collected via a structured in-home interview conducted
by trained study nurses that included information on self-described race and ethnicity,
family history of CaP, and detailed information on demographic characteristics, diet, and
health history.
We used genotype data from Illumina iControlDB (http://www.illumina.com) as controls.
Illumina's iControlDB is a freely available, online database of genotype and phenotype data
from individuals that can be used as controls in association studies[17] . Control genotype
data generated using the Illumina HumanHap550 chip were downloaded from the Illumina's
web site for 1260 EA and 925 AA men who had > 90% complete genotype data.
SNP selection
We designed a panel of SNPs for prostate cancer using our previously described SNPinfo
web server (www.niehs.nih.gov/snpinfo) [18]. SNPinfo provides an integrated SNP-
selection platform that incorporates primary data from previous GWAS studies, population-
specific linkage disequilibrium, and detailed functional predictions based on coding,
transcription factor binding, splicing, and miRNA binding. We selected SNPs using three
pipelines: GenePipe for candidate genes (121 SNPs), LinkPipe for linkage regions (225
SNPs), and GenomePipe for the overall genome (200 SNPs) with details of parameter
settings of SNPinfo provided in the supplemental materials. In addition, a set of “a priori”
SNPs included 205 SNPs from published CaP GWAS and validation studies available at the
time of panel selection [4-8,19-22] and 55 SNPs that had association P<0.01 in both
CGEMS GWAS [6] and Framingham GWAS [23].
These a priori SNPs supplemented the SNPs chosen via SNPinfo and together included a
total of 32 “replicated SNPs”, i.e. SNPs that were the primary findings of GWAS and
replication studies, representing 21 different chromosomal regions, (see Supplementary
Table 1). Not all of these SNPs had been established as replicated SNPs at the time of our
selection. Additionally, our SNP set included 35 “flanking SNPs” that are located near
replicated SNPs.
To control for population stratification, we selected 50 ancestry informative SNP markers
(AIMs) based on allele frequency data in HapMap phase I+II populations
(http://hapmap.ncbi.nlm.nih.gov). Twenty five of these SNPs are monoallelic (variant allele
frequency (VAF) = 0) in CEU (US residents with ancestry from Northern and Western
Europe, collected by the Centre d'Etude du Polymorphisme Humain (CEPH)), rare in Asians
(VAF < 0.01) but very common in populations of African ancestry (YRI, Yoruban from
Nigeria, VAF > 0.65 and AA VAF > 0.25). Additionally 25 SNPs are monoallelic (VAF =
0) in YRI, rare in Asians (VAF < 0.05), but very common in CEU (VAF > 0.5).
Genotyping
DNA was extracted from blood samples (n=796) by the UNC-CH Biospecimen Processing
Facility, or from peripheral blood mononuclear cells immortalized by the UNC-CH Tissue
Culture Facility (n=89). Genotyping was performed by the Center for Inherited Disease
Research (CIDR) at Johns Hopkins University using a custom designed 1,536 SNP Illumina
GoldenGate array. Genotyping included a set of 22 blind duplicates, and a set of HapMap
controls comprised of 8 CEU and 11 YRI trios.
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Associations of individual SNPs with CaP were tested using unconditional logistic
regression assuming a log-additive genotypic model where genotypes were coded as 0, 1, or
2 according to the number of “risk alleles” identified in European-based GWAS for the 32
replicated SNPs (Supplemental Table 1), or the number of minor alleles (for all other SNPs).
A P value threshold of P < 0.05 was used for the set of 32 a priori replicated SNPs and a
Bonferroni-corrected study-wide P < 3.55 × 10−5 (based on 723 SNP comparisons in both
EA and AA populations) was used for all other SNPs. The proportion of European or West
African ancestry was used to adjust for population stratification. Ancestry proportion was
estimated using STRUCTURE[24] based on AIMs. HapMap genotype data for 209
independent individuals from CEU, YRI, CHB and JPT populations were used to assist with
individual ancestry estimation.
The “risk allele” reported in European-based GWAS was identified for each of the 32
replicated SNPs. The number of risk alleles was summed for each research subject. Receiver
Operating Characteristic (ROC) curves were used to estimate the predictive accuracy of risk
allele counts as a method to discriminate cases from controls.
Simulation
Simulation was used to construct expected P value distributions after case-control sampling
under different allele frequency scenarios. Two sets of 10,000 simulations were conducted:
one where the risk (minor) allele frequency differed in cases (MAF = 0.29) and controls
(MAF = 0.25), and a second, under the null, where risk (minor) allele frequencies were
identical (MAF = 0.27). In each simulation, 500 cases and 500 controls were sampled
randomly. Only those simulations where the major allele appeared to be the risk allele
(discordant) were considered. Fisher's exact test was used to generate P values.
Results
Allele calling was conducted using Illumina's Genotyping Module version 1.0.10 in
GenomeStudio 1.0.2.20706. The genotype intensity cluster plots were visually inspected for
each SNP. Individual genotypes with an Illumina GenCall (GC) score below 0.25 were
assigned as missing. Six PCaP study subjects were excluded due to poor genotyping
performance. Seventy seven (9.6%) SNPs were excluded from association analysis due to a
poor clustering pattern or parent-parent-child (P-P-C) heritability errors identified based on
HapMap trios. The overall subject genotyping call rate was 99.95%. The reproducibility rate
was 99.99% based on blind duplicates and the overall P-P-C heritability based on HapMap
trios was 99.95%.
Quality control analysis was performed on the 723 SNPs that were typed in our panel and
the iControlDB. iControlDB genotype data was checked for erroneous duplicates and related
subjects and excluded 48 EA and 42 AA men with an identity by state (IBS) score > 1.6
with another iControlDB subject [17]. Hardy-Weinberg Equilibrium (HWE) was assessed at
each SNP locus in iControlDB using the Fisher's exact test. 13 SNPs in EAs and 18 SNPs in
AAs were excluded because HWE P values were ≤ 0.01.
For the remaining PCaP cases (n = 879) and iControlDB control subjects (n = 2095) that
passed quality control criteria, individual ancestry was estimated using AIMs and the
software STRUCTURE[24]. We excluded 5 PCaP cases and 41 iControlDB controls that
self-identified as EA but had less than 85% European ancestry, and excluded 2 PCaP cases
and 13 iControlDB controls that self-identified as AA but had more than 10% Asian
ancestry. The ancestry estimates for the remaining individuals are shown in Supplementary
Figure 1. PCaP EA men (n=455) had an average proportion of European ancestry of
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0.98±0.02, which is almost identical to that observed in EA iControlDB men (n=1171,
European ancestry 0.98±0.02). PCaP AA men (n=417) had an average proportion of African
ancestry of 0.89±0.12 and European ancestry of 0.10±0.12; which is almost identical to
iControlDB AA men (n=870, African ancestry 0.89±0.16, European ancestry 0.10±0.16).
Our SNP panel included 32 replicated SNPs from European-based GWAS and, an additional
35 flanking SNPs (Figure 1 and Supplementary Table 1). Of the 32 replicated SNPs, 13
were significantly associated (P <0.05) with CaP in EA and 4 in AA, with 3 SNPs
significantly associated with CaP in both populations (Table 1). Associations with 3 of the
35 flanking SNPs reached the study-wide significance level (P < 3.55 × 10−5) including one
in EA and two in AAs; all 3 are located on chromosome 8q24 in regions 2, 4, and 5 (Figure
1, Table 1, and Supplementary Table 1). Associations with two of the remaining 656 SNPs
reached the study-wide significance level (P < 3.55 × 10−5): SNP rs9351265 among AAs
and SNP rs1472606 among EA (Table 1). These SNPs are located in intergenic regions on
chromosomes 6q16.1 and 5q35.2, respectively.
For the 32 replicated SNPs we also examined whether the risk allele identified from
European-based GWAS was concordant with the risk allele identified in our study
populations, independent of statistical significance (Supplemental Table 2). We found that
PCaP EA risk alleles were concordant with GWAS reported European risk alleles for 27 of
32 SNPs, including all 13 SNPs with association P values <0.05 (Figure 2a).
We also explored concordance between European-based GWAS risk alleles and the risk
alleles for AA in our study (Supplemental Table 2). Under the null hypothesis that these
SNPs are not associated with CaP in AA, equal numbers of concordant and discordant SNPs
would be randomly distributed along the diagonal when rank-ordered by association P value
(Figure 2B). Although we observed approximately equal numbers of concordant (n=18) and
discordant (n=14) SNPs that roughly followed the diagonal, an unusual pattern emerged
where concordant SNPs were distributed across lower P values (mean P value = 0.20) and
discordant SNPs were distributed across higher P values (mean P value = 0.67) (Wilcoxon
rank sum test, p=1.5×10−5 and Student's t test t= 3.17, p= 0.0074). In order to explore this
unusual pattern we simulated samples of cases and controls from populations with minor
allele frequencies that were either identical or had slight differences (4%). Under the null
(where simulated case and control populations had identical allele frequencies) discordant
SNPs had the expected random distribution of association P values ranging from 0 to 1
(Supplementary Figure 2A). When simulated case and control populations had slightly
different allele frequencies (i.e., where SNPs have a “true” association with disease),
discordant SNPs had a distribution of association P values that were significantly skewed
toward higher values – similar to that observed in our data (Supplemental Figure 2B).
Receiver Operator Characteristics
The number of risk alleles (as identified from European-based GWAS studies) for the 32
replicated SNPs were counted for each individual among PCaP cases and iControlDB
controls. Mean risk allele counts were 26.1 (SD 4.6) and 24.4 (SD 4.2) for EA cases and
controls (Student's t-test P = 1.7×10−11) and 28.0 (SD 3.8) and 27.2 (SD 3.8) (Student's t-test
P =3.6×10−4) for AA cases and controls (Figure 3A and B).
Receiver Operator Characteristic (ROC) curve plots for EA and AA are shown in Figure 3.
Each point represents a different observed cumulative risk allele count. Sensitivity (true
positive fraction) and 1 – Specificity (false positive fraction) are plotted. An optimal test
maximizes sensitivity and minimizes the false positive fraction. An AUC of 0.5, shown by
the dotted diagonal, represents a test with no ability to differentiate between cases and
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controls. AUCs were 0.60 (95% CI: 0.57-0.63) and 0.56 (95% CI: 0.53-0.60) for EA and
AA, respectively.
Discussion
Prostate cancer genetics is relatively advanced in that there have been several large GWAS
and multiple large-scale replication studies published to date—however the majority of these
studies were of men of European descent[5-8,10,19,21,22,25-28]. To validate previous
GWAS findings and identify additional SNPs associated with PCaP, we selected and
analyzed 800 SNPs with the assistance of SNPinfo web tools[18]. This panel included 32
replicated SNPs representing 21 distinct chromosomal regions reported by previous GWAS,
and 35 flanking SNPs in these regions. The genotypes for AA and EA CaP cases were
compared to iControlDB controls – a publically available dataset of individual genotypes
from selected racial groups that has been established for use in genetic association studies.
This database has been used in 19 published association studies and shown to produce
results that are comparable to those reported in matched case-control analyses (see
supplementary text for the list of related peer reviewed publications). Similar to the methods
employed by other studies, we controlled for population stratification by removing outliers
based on ancestry proportion estimates from STRUCTURE analysis. Both PCaP AA and EA
cases are genetically well-matched to iControlDB AA and EA controls (Supplementary
Figure 1). Although use of iControlDB controls has been established in multiple
publications, these men were not explicitly screened for prostate cancer and thus may harbor
undetected disease. Such misclassification of controls would be expected to lead to a slight
bias toward the null and could reduce the number of GWAS hits confirmed in this case-
control association analysis.
Given that 32 SNPs in our panel had already been established by previous GWAS studies,
we used the 0.05 significance level when testing for association. Nearly half of the 32 SNPs
achieved nominal significance at P = 0.05 level in EA men. Despite AA men having a
higher incidence of prostate cancer, no CaP GWAS of AA has been published to-date, and
AA men have been underrepresented in replication studies. There have been a total of 5
replication studies examining European GWAS hits that have included African Americans
[8,12-15]. These studies collectively examined 24 of the 32 replicated SNPs (Supplementary
Table 2) surveyed in our panel and reported 6 SNPs (rs2660753 chr 3, rs6983267 chr 8,
rs10896449 chr 11, rs4430796 chr 17, rs2735839 chr 19 and rs 5945572 chr X) that showed
significant evidence of CaP association in at least one study of AA. In our study, 4 of the 32
SNPs demonstrated CaP associations in AA, including one (rs6983267 on chr 8) of the 6
SNPs previously reported. The remaining 3 SNPs (rs 7017300 chr 8, rs1859962 chr 17 and
rs6501455 chr 17) are here identified as risk factors for CaP in AA for the first time. Thus,
there are now a total of 9 SNPs that have been associated with CaP in AA.
The lack of confirmation in AA for many of the 32 European-based GWAS and the
inconsistency of associated genetic variants identified in AA populations may be explained
in part by the relatively small number of studies of AA reported to date as well as the
relatively small sample size within each study. But more importantly, the lack of association
may be related to the fact that LD structure often differs between EA and AA populations
and GWAS hits are typically marker SNPs in linkage disequilibrium (LD) with causal
alleles. Therefore, differences in LD structure between EA and AA populations may
diminish the strength of associations when European-based marker SNPs are applied to AA
populations. Thus, even if EA and AA share common causal alleles, the set of marker SNPs
that show strong association in EA may show little or no association in AA. It is interesting
to note that in our analysis we found an unexpected pattern: SNPs with discordant risk
alleles between previous EA GWAS and PCaP AA tend to have large association P values
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and SNPs with concordant risk alleles tend to have small association P values. We
demonstrate through simulation that when there is no difference in allele frequency between
cases and controls, associations with discordant risk alleles will produce the expected
random distribution of P values. However when allele frequencies differ between cases and
controls (indicating an association with disease), associations with discordant risk alleles
will be skewed toward high P values. Thus, although we only observe associations between
CaP and 4 SNPs among AA, the distribution of discordant risk alleles may suggest that this
set of 32 SNPs define loci important for CaP risk in AA.
Given the different LD structure of the AA population we also included a set of 35 SNPs
adjacent to the 32 GWAS SNPs. Two SNPs reached study-wide significance in AA and one
in EA, and all came from different subregions of 8q24. These 3 flanking SNPs produce a
stronger signal than their corresponding replication SNPs (which were also significant),
however, the flanking and replication SNPs are not in strong LD. Thus, these flanking SNPs
may provide additional information for fine mapping of causal alleles in these chromosomal
regions.
In addition to examining GWAS hits and related flanking SNPs, additional CaP SNPs were
sought using our web-based SNP selection software tool SNPinfo[18]. This program allows
researchers to combine GWAS information with linkage and functional data along with
population-specific LD information for SNP selection. In constructing our panel, 5 SNPs
(rs11649743, rs4857841, rs12543663, rs8102476 and rs620861) were included in 5
chromosome regions that were later reported as GWAS hits[10,25,27,28], – thus
highlighting the utility of our selection approach. However, 2 of these SNPs (rs8102476 and
rs620861) were subsequently excluded because of poor Illumina design scores. We found
two SNPs that reached study-wide significance, one in EA (rs1472606) and one in AA
(rs9351265). SNP rs1472606 is located on chromosome 5q35 within a reported copy
number variant [29] about 90 kb from the transcription start site of HRH2, a G-coupled
histamine receptor gene. This SNP was previously demonstrated to have strong evidence of
linkage in 606 CaP families with early age at diagnosis (≤ 65 years) [30]. To our knowledge,
this is the first population-based study to identify this SNP as having a strong association
with CaP risk, although the CGEMS GWAS showed some signal for this SNP as well (P =
0.0016, rank = 1098) [6]. The second SNP, rs9351265 is located at chromosome 6q16.1 in a
gene-poor region 800 kb upstream from the transcription start site of MAP3K7. Although
not previously examined in AA, both the CGEMS follow-up study and Thomas, et. al. [7],
also found evidence of association with CaP in Europeans (CGEMS p=0.00067, rank = 135;
Thomas et al p< 0.001 rank 184). In addition, Liu, et al., [31] found a deletion 820kb from
rs9351265 associated with high-grade prostate cancers.
There has been growing interest in the use of genetic profiles for personalized medicine.
Existing genetic panels are being marketed for prediction of disease risk, although the
predictive power of many of these have yet to be clearly demonstrated [32]. For CaP, Zheng,
et. al., [33] suggested that an individual's allele counts for 5 SNPs correlated with increasing
risk in Swedish men. In a subsequent study of US men, Salinas, et. al., confirmed that these
5 SNPs were significantly associated with risk, but the ROC curves obtained using clinical
variables (AUC = 0.63) were not improved by inclusion of SNP information (AUC = 0.66)
[34]. It has been suggested that an AUC > 0.75 may provide an appropriate threshold for
screening tools in high risk populations, while an AUC > 0.99 may be required for general
population screening [32]. In our study using a much larger panel of 32 SNPs whose
association with prostate cancer had been established a priori in previous GWAS replication
studies, risk allele counts differed significantly between cases and controls (Europeans P =
1.7 × 10−11). Despite the profound difference in allele counts, the ROC curve analysis of our
data shows poor discriminatory power for both EA (AUC=0.60; 95% CI: 0.57-0.63) and AA
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(AUC= 0.56; 95% CI: 0.53-0.60). In part, this may be due to disease heterogeneity, if
multiple subtypes of CaP have distinct genetic and environmental risk determinants. In
addition, genetic heterogeneity is likely in CaP, meaning that different variations in the same
gene, or variations across multiple genes (a number of which have yet to be identified), may
also contribute to genetic susceptibility. While finer mapping may provide better
characterization of causative SNPs and improve the clinical utility of CaP genetic panels, it
is clear that our current panel is not adequate for general clinical use, even among high risk
individuals.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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P values for CaP associations with 67 SNPs in 21 chromosome regions in African
Americans (triangles) and European Americans (circles), including 32 replication-SNPs
previously reported in GWAS papers (solid symbols) and 35 flanking SNPs (open symbols).
The lower dotted line represents the unadjusted significance threshold of 0.05 for GWAS
reported SNPs; the upper dotted line represents the study-wide adjusted significance
threshold for all other SNPs (Bonferroni corrected for test of 723 SNPs in both AA and EA
analysis).
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Rank-order of association P values for 32 replication-SNPs. Risk alleles were identified
from European-based GWAS and concordance with PCaP risk alleles is shown as solid
circles (concordant) or open triangles (discordant). Under the null hypothesis that none of
the SNPs are associated with CaP there should be equal numbers of concordant and
discordant alleles and within each category and SNPs should have association P values that
are randomly distributed along the diagonal from 0 to 1. A) SNPs for PCaP EA show
significantly higher than expected numbers of concordant risk alleles and SNPs with
association P-values < 0.05. B) SNPs for PCaP AA have similar numbers of concordant and
discordant alleles and association P values largely fall along the diagonal. However, there
are more SNPs than expected below association P value 0.05 (4 vs. 1.6 expected) and the
distribution of concordant and discordant SNPs is nonrandom with significantly more
discordant SNPs at higher association P values (Wilcoxon rank-sum test P = 1.5×10−5).
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Frequency distribution of risk allele counts for 32 replicated SNPs in PCaP cases and
Illumina iControlDB controls for AA (panel A) and EA (panel B). Risk alleles were
identified from European-based GWAS. Mean counts differ significantly between cases and
controls for both AA and EA race groups. Receiver Operating Characteristic (ROC) curves
for AA (panel C) and EA (panel D) are provided to demonstrate the discriminatory ability of
risk allele counts to correctly classify cases and controls, as necessary for clinical testing.
AUC values of ≥ 0.75 have been proposed for high risk groups and AUC ≥ 0.99 for general
population screening [32].
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